 Older CLL patients are undertreated when compared to younger ones, while costly procedures are mainly offered to patients under the age of 66. Although it is irrefutable that some health changes appear with age, "advanced" age alone should not be a contraindication for treatments that can improve patient's survival or quality of life. On the other hand, older people make a significant contribution to society, which can be fostered by helping them maintain good health.
INTRODUCTION
 Chronic lymphocytic leukemia (CLL) is the most common leukemic disease in the Western World 1 , with an incidence of 4.2/100,000 cases per year 2 . However, CLL is primarily a disease of the elderly, with a median age at diagnosis of 72 years 2 . Over the age of 65, the number of new diagnoses increases to 22-30/100,000 3 , and to more than 30/100,000 cases beyond 80 years 2 .
 Survival in CLL has significantly improved in recent years. Nevertheless, age-related disparities persist and many elderly patients currently receive suboptimal treatment 4 , showing lower survival rates 5 . Greater awareness of this problem may improve survival for older patients with CLL.
OBJECTIVE
To review the literature relating age as a determinant of therapeutic decisions in CLL and search for evidence of ageism in the access to treatment of elderly patients.
METHODS
 Electronic databases [MedLine/PubMed] and grey literature [Google Scholar, congress proceedings, technical reports] were searched to identify publications investigating ageism in oncology to comprehensively address the complex problematic of age discrimination with a particular focus on 1) CLL treatment, 2) economic and social costs and 3) social value of the elderly. Studies in English or Spanish published until December 2015 were considered.
RESULTS
 A total of 31 publications were considered relevant to review (Figure 1 ).
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Cost-of-illness on elderly
 CLL imposes a high economic burden, primarily driven by pharmaceutical 24 and inpatient costs [16] [17] [18] (Table 1) .
 High pharmaceutical costs attributable to the rapid emergence of new healthcare technologies 14 .
Cost-effectiveness ratio of innovative treatments for hematologic malignancies has been stablished in $50,000 -100,000/QALY 15 . In this sense, health care policymakers should ensure affordable treatment and make certain cost considerations to not deprive patients from lifeprolonging therapy 14, 22 .
 The costs of the disease differ by age group 17 . The average yearly cost for each CLL patient increases with advancing age (>65), while for non-CLL patients they increase steadily until the age of 85, with the cost difference decreasing to zero at 85 17 ( Figure 3 ). Younger patients are more extensively treated for CLL to increase their chances of survival. Costly procedures might be used only for patients under the age of 66 17 .
All costs were updated to 2016 Spanish Euro using the 'CCEMG -EPPI-Centre Cost Converter' (v.1.5 last update: 29 April 2016). 7, 35 •Clinical trials performed in individuals 10 to 15 years younger than median age at diagnosis of CLL (72 years) 7 . Therefore, there is no consensus on how to manage aged patients
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Inclusion of older people with no age restriction in clinical trials
Age discrimination 35 •Elderly CLL patients (>70 years) are treated less effectively and frequently (p<0.001), and therefore have lower response rates (p<0.001), than younger ones 10 •Older patients with CLL do better emotionally than younger ones 6 , being less depressed (p= 0.014) and with an increased emotional (p= 0.0001) and social (p= 0.002) quality of life. Moreover, they want to retain choice and control of decision making 28
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• Decision-making on the care and treatments mostly based on chronological age 8, 27 Biological age ( 
